Mergers and Acquisitions29 Apr 2026
Eli Lilly has partnered with AI biotech Profluent Bio in a research pact potentially worth up to $2.25 billion to develop advanced DNA editing tools. The...
Mergers and Acquisitions29 Apr 2026
Belén Garijo takes over as Sanofi CEO on April 29, facing the critical challenge of preparing the company for life after Dupixent's patent expiry, expected as...
Mergers and Acquisitions28 Apr 2026
Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, marking its third oncology deal in three weeks. The acquisition focuses on Ajax's lead...
Mergers and Acquisitions28 Apr 2026
Sun Pharmaceutical is set to acquire Organon for $11.75 billion in an all-cash transaction, aiming to significantly bolster its global presence in biosimilars...
Mergers and Acquisitions24 Apr 2026
PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, announced the acquisition of a global antiviral asset portfolio. This strategic move...
Mergers and Acquisitions24 Apr 2026
Plus Therapeutics announced the initiation of manufacturing activities and technology transfer with SpectronRx under a Master Services Agreement (MSA) to...
Mergers and Acquisitions24 Apr 2026
Amneal Pharmaceuticals has acquired Kashiv BioSciences in a $1.1 billion deal, comprising $375 million in cash, $375 million in equity, and up to $350 million...
Mergers and Acquisitions23 Apr 2026
Eli Lilly has terminated its partnership with Rigel Pharmaceuticals for two investigational RIPK1 inhibitors, effective June 15. This decision means Lilly will...
Mergers and Acquisitions22 Apr 2026
Tortugas Neuroscience, a new biotech led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, has launched with $106 million in funding. The...
Mergers and Acquisitions22 Apr 2026
Eli Lilly is set to acquire Kelonia Therapeutics for up to $7 billion, including an upfront payment of $3.25 billion, significantly bolstering its presence in...
Mergers and Acquisitions22 Apr 2026
UCB is set to acquire California-based Neurona Therapeutics for an upfront payment of $650 million, with potential milestone payments reaching up to $500...
Mergers and acquisitions27 Oct 2025
Novartis AG will acquire Avidity Biosciences for USD 72.00 per share in cash, valuing the company at approximately USD 12.0 billion. Avidity will sepa...
Mergers and acquisitions22 Oct 2025
Innovent Biologics and Takeda have entered into a global strategic partnership to co-develop and commercialize Innovent's next-generation immuno-oncol...
Mergers and acquisitions16 Oct 2025
Biocon Biologics and Civica expand their partnership to include Insulin Glargine, aiming to increase the availability of affordable insulin for the 38...
Mergers and acquisitions16 Oct 2025
Boehringer Ingelheim and AimedBio have entered into a global collaboration and licensing agreement to develop a novel antibody-drug conjugate (ADC) th...
Mergers and acquisitions09 Oct 2025
Akero Therapeutics, a clinical-stage company focused on metabolic diseases, has entered into a definitive agreement to be acquired by Novo Nordisk for...
Mergers and acquisitions07 Oct 2025
MaxCyte and Moonlight Bio have entered into a Strategic Platform License agreement. Moonlight Bio will utilize MaxCyte’s Flow Electroporation® technol...
Mergers and acquisitions02 Oct 2025
Elutia Inc. has finalized the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation for $88...
Mergers and acquisitions18 Sept 2025
Roche has entered into a definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical company, for up to $3.5 billion. The a...
Mergers and acquisitions09 Sept 2025
Novartis announced its acquisition of Tourmaline Bio, a clinical-stage biopharmaceutical company, for approximately $1.4 billion. The acquisition cen...
Mergers and acquisitions05 Sept 2025
Zydus Lifesciences and Synthon BV have entered into an exclusive licensing and supply agreement for Ozanimod Capsules, a generic version of ZEPOSIA®, ...
Mergers and acquisitions02 Sept 2025
Polpharma Biologics and MS Pharma have signed licensing agreements for the commercialization of three biosimilar candidates: vedolizumab (PB016), ocre...
Mergers and acquisitions02 Sept 2025
Servier and IDEAYA Biosciences announced an exclusive license agreement for darovasertib, a PKC inhibitor, for uveal melanoma treatment outside the US...
Mergers and acquisitions29 Aug 2025
LakeShore Biopharma Co., Ltd. announced the receipt of a revised preliminary non-binding proposal from a consortium (Oceanpine Capital and Crystal Pea...
Mergers and acquisitions26 Aug 2025
AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' bretisilocin, a novel Phase 2 psychedelic compound for treating moderate-to-severe majo...
Mergers and acquisitions20 Aug 2025
AbbVie has completed its acquisition of Capstan Therapeutics, gaining access to CPTX2309, a first-in-class in vivo targeted lipid nanoparticle (tLNP) ...
Mergers and acquisitions14 Aug 2025
AleraCare, a provider of infusion and specialty pharmacy services, and PURE Healthcare, a medical group specializing in treating chronic conditions, a...
Mergers and acquisitions07 Aug 2025
CorMedix Inc. announced a definitive agreement to acquire Melinta Therapeutics LLC for $300 million. This acquisition significantly expands CorMedix's...
Mergers and acquisitions07 Aug 2025
Melinta Therapeutics, a commercial-stage biopharmaceutical company focused on acute and life-threatening illnesses, has been acquired by CorMedix Inc....
Mergers and acquisitions04 Aug 2025
Demetra, a medical company specializing in bone cements and biomaterials, announced the acquisition of OrthoFundamentals, a provider of single-use sol...
Mergers and acquisitions04 Aug 2025
Mallinckrodt plc and Endo, Inc. have completed their merger, forming a global leader in diversified therapeutics. The combined company boasts a broad ...
Mergers and acquisitions04 Aug 2025
Arrowhead Pharmaceuticals announced that its subsidiary, Visirna Therapeutics, has sold the rights to its investigational drug, plozasiran, for the tr...
Mergers and acquisitions28 Jul 2025
Adaptimmune Therapeutics plc announced the sale of its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million in cas...
Mergers and acquisitions28 Jul 2025
Hengrui Pharma and GSK have entered into agreements to co-develop up to 12 innovative medicines across respiratory, immunology & inflammation, and onc...
Mergers and acquisitions25 Jul 2025
Gate Bioscience, a biotechnology company focused on molecular gate technology, announced a collaboration and license agreement with Eli Lilly and Comp...
Mergers and acquisitions17 Jul 2025
Thermo Fisher Scientific announced an expansion of its strategic partnership with Sanofi. Thermo Fisher will acquire Sanofi's sterile manufacturing s...
Mergers and acquisitions16 Jul 2025
Repare Therapeutics has entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, a first-in-class PKMYT1 inhibitor. D...
Mergers and acquisitions15 Jul 2025
Cantargia AB has announced an agreement with Otsuka Pharmaceutical for the acquisition of Cantargia's CAN10 program. Otsuka will acquire all assets r...
Mergers and acquisitions10 Jul 2025
Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding (MoU) to collaborate on the industrialization and scal...
Mergers and acquisitions09 Jul 2025
Merck has agreed to acquire Verona Pharma for approximately $10 billion. This acquisition brings Ohtuvayre (ensifentrine), a first-in-class COPD main...
